FDA Skeptical of Experimental Gene Therapy for Rare Muscle Disease
TL;DR Summary
Parents of children with Duchenne muscular dystrophy are advocating for the accelerated approval of an experimental gene therapy, SRP-9001, which aims to slow or stop the progression of the disease. The therapy uses viruses to deliver a copy of a gene to muscles to help make up for one that’s causing the disease. However, the FDA is skeptical about its effectiveness and safety, particularly related to the possibility of administering an ineffective gene therapy. The FDA's decision, expected by the end of the month, will have implications for how the agency regulates treatments like this one more broadly.
Topics:business#clinical-trials#duchenne-muscular-dystrophy#fda#gene-therapy#health#sarepta-therapeutics
- Families facing rare muscle disease are pushing for an experimental gene therapy, but the FDA is skeptical CNN
- These parents say new treatment helped their son with muscular dystrophy. The FDA isn't convinced KTBS
- These parents say new treatment helped their son with muscular dystrophy. The FDA isn't convinced CNN
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
6 min
vs 7 min read
Condensed
92%
1,278 → 98 words
Want the full story? Read the original article
Read on CNN